Medication deprescribing sits at the center of this dementia and brain health question.

Deprescribing—the systematic reduction or discontinuation of medications that may no longer benefit a patient—has emerged as a promising strategy for improving medication safety and quality of life in dementia patients. While claims of a single program achieving 30% cognitive improvements should be viewed cautiously (such specific outcomes have not been consistently documented in available clinical trials), the evidence does support that carefully managed deprescribing can produce meaningful gains. Recent research shows that medication optimization interventions are generally safe, can improve activities of daily living, and may reduce the burden of unnecessary drugs that sometimes cloud thinking or complicate care. This article explores the science behind deprescribing programs, what the research actually shows about cognitive outcomes, how these programs work in practice, and how to determine whether deprescribing is appropriate for someone in your care.

Deprescribing is not about eliminating all medications—it’s about eliminating the right ones. Many dementia patients accumulate medications over years, some prescribed for conditions that have resolved, others for side effects caused by previous drugs, and still others that provide minimal benefit relative to their risks. For some patients, this medication burden itself becomes a source of cognitive fog, falls, incontinence, and behavioral changes. The programs that show the most promise focus on high-risk medication classes: antipsychotics, sedative-hypnotics, anticholinergics, and other drugs known to impair cognition or increase dangerous side effects in older adults.

What Does Deprescribing Actually Mean in Dementia Care?
What Does Research Show About Cognitive Outcomes?
Which Medication Classes Benefit Most from Deprescribing?
How Are Deprescribing Programs Structured in Clinical Practice?
What Are the Main Barriers and Risks in Deprescribing Programs?
Real-World Examples: When Deprescribing Succeeds
The Future of Deprescribing: Emerging Guidelines and Trials
Conclusion

What Does Deprescribing Actually Mean in Dementia Care?

Deprescribing is a structured clinical process—not a sudden stop of medications, but a gradual, monitored reduction guided by medical professionals. In dementia patients, this typically targets medications that either have limited evidence of benefit for that particular person, carry high risks of cognitive or physical harm, or were prescribed for conditions that are no longer relevant. A 2025 roadmap published in peer-reviewed literature emphasizes that deprescribing must be personalized and should begin with patient and family education at the time medications are first prescribed, establishing clear expectations about whether each drug serves a long-term role. The distinction matters because not all medications should be deprescribed in dementia.

Medications that genuinely control symptoms, prevent serious disease progression, or stabilize mood often remain essential. The goal is to identify and remove the ones causing more harm than good. For example, a patient on an anticholinergic medication for urinary symptoms might find that the medication’s cognitive side effects outweigh its benefit, particularly if the urinary symptom itself is manageable through other means. A patient on a second antipsychotic for behavioral symptoms that have since resolved is another clear candidate for deprescribing.

What Does Deprescribing Actually Mean in Dementia Care?

What Does Research Show About Cognitive Outcomes?

The research landscape is more nuanced than headlines about “30% cognitive improvements” suggest. A comprehensive systematic review examining medicine optimization and deprescribing interventions in older adults with dementia or mild cognitive impairment found that these programs were generally safe and did not worsen clinical outcomes—an important baseline finding. However, the same review noted that cognitive improvements were inconsistently reported across studies, meaning that while some patients showed cognitive gains, others showed no change, and the effects were not uniform. The COSMOS trial, one of the largest deprescribing studies, examined nursing home residents who were deprescribed from psychotropic medications.

The trial found improvements in activities of daily living—meaning patients could function more independently—but the cognitive outcomes were not the primary focus. The D-PRESCRIBE-AD trial, completed in 2024, tested educational interventions aimed at reducing high-risk medications like antipsychotics, sedative-hypnotics, and anticholinergics in Alzheimer’s disease patients. However, the results revealed a limitation: even with medical education and support, 76-78% of patients continued using the targeted high-risk medications, suggesting that deprescribing is more difficult to sustain in practice than in theory. This gap between intention and outcome is important to understand: promising programs can face real barriers to implementation.

Which Medication Classes Benefit Most from Deprescribing?

Anticholinergic medications—drugs that block acetylcholine, a neurotransmitter important for memory and attention—are among the strongest candidates for deprescribing in dementia. These include some over-the-counter antihistamines, certain antidepressants, and medications prescribed for urinary or digestive symptoms. A growing body of evidence links anticholinergic burden to cognitive decline, and ongoing trials like the R2D2 study (currently enrolling 344 older adults) are specifically measuring whether deprescribing these drugs improves cognition over 6 to 24 months. Results from R2D2 may provide clearer guidance on the cognitive impact of anticholinergic reduction.

Sedative-hypnotics and antipsychotics are also frequent targets. Benzodiazepines and newer sedatives can increase fall risk, confusion, and dependency, particularly in older adults. Antipsychotics, while sometimes necessary for severe behavioral symptoms, carry black-box warnings in dementia and are overprescribed as a result of habit or convenience rather than genuine medical need. The challenge is that deprescribing these medications requires clinical oversight because stopping them abruptly can cause rebound anxiety, insomnia, or behavioral escalation. The programs that work best use slow tapering, behavioral monitoring, and family communication to manage the transition safely.

Which Medication Classes Benefit Most from Deprescribing?

How Are Deprescribing Programs Structured in Clinical Practice?

Successful deprescribing programs follow a systematic approach. The first step is a comprehensive medication review, often performed by a pharmacist or geriatrician, to identify which drugs are candidates for reduction. The second step is establishing goals with the patient and family—clarifying what outcomes matter most, whether that is cognitive clarity, reduced side effects, fewer doctor visits, or better mood and function. The third step is education: explaining why each targeted medication may be causing more harm than benefit and what to expect during the reduction process. The fourth step is the gradual reduction itself, often called a taper.

For some medications, this might mean reducing the dose by 10-25% every few weeks; for others, it might involve switching to a shorter-acting alternative and then gradually reducing that. The fifth step—often overlooked but critical—is monitoring. During and after deprescribing, patients need regular follow-up to assess for worsening behavior, new symptoms, or unexpected declines. A patient whose confusion briefly worsens during a benzodiazepine taper may need reassurance and a slower reduction schedule, rather than being told the deprescribing has failed. This individualized, stepwise approach is reflected in the 2025 deprescribing roadmap and contrasts sharply with older practices of abrupt drug cessation.

What Are the Main Barriers and Risks in Deprescribing Programs?

One major barrier is clinician and family resistance. Doctors sometimes prescribe medications defensively (“the patient asks for it” or “it’s safer than the alternative”) without periodically reassessing whether the drug still serves the original purpose. Families, seeing a medication in the pill organizer, may fear that removing it will cause a decline. Both assumptions can be incorrect, but overcoming them requires time, education, and trust—resources that are scarce in many healthcare settings. The D-PRESCRIBE-AD trial’s finding that 76-78% of patients continued targeted high-risk medications illustrates this real-world friction.

Another risk is rebound phenomena. Stopping an antipsychotic or benzodiazepine abruptly, or even too quickly, can trigger severe behavioral disturbances, anxiety, or seizures. This is why deprescribing must be gradual and monitored. Additionally, some cognitive decline in dementia occurs naturally with disease progression, and it can be difficult to disentangle whether an observed change is due to the disease, the medication reduction, or external factors like infection or medication interactions. Programs that succeed include close clinical monitoring and clear documentation of baseline and post-deprescribing function.

What Are the Main Barriers and Risks in Deprescribing Programs?

Real-World Examples: When Deprescribing Succeeds

A common successful case involves an older adult with mild dementia who was prescribed a medication for urinary incontinence several years ago. The drug—an anticholinergic—worked for the incontinence but over time, family members noticed increased confusion, slower thinking, and occasional word-finding problems. A geriatric pharmacist reviewed the medication list and identified the anticholinergic as a likely culprit. After a conversation about risks and benefits, the doctor gradually reduced the dose over four weeks.

The patient continued the medication temporarily at a lower dose, then discontinued it. Within two to three weeks after full discontinuation, family members reported clearer conversation, better recall of recent events, and improved engagement. The incontinence returned slightly, but it was managed through behavioral strategies like timed toileting and fluid management. This type of outcome—modest cognitive improvement after removing a clearly harmful drug—aligns with what the research actually shows.

The Future of Deprescribing: Emerging Guidelines and Trials

The field is evolving rapidly. The 2025 deprescribing roadmap emphasizes that deprescribing should begin at treatment initiation, not years later. In other words, the best time to avoid problematic medications is to not prescribe them in the first place, with clear plans for reassessment. Ongoing trials like R2D2 will provide more specific evidence about the cognitive impact of anticholinergic deprescribing, which may lead to more confident clinical recommendations.

Similarly, newer deprescribing programs are incorporating digital tools, remote monitoring, and pharmacist-led interventions to overcome logistical barriers and improve success rates. As evidence accumulates, deprescribing is transitioning from a fringe practice to mainstream geriatric medicine. Guidelines from major medical organizations increasingly recommend periodic medication reviews and deprescribing for older adults, including those with dementia. This shift reflects a growing recognition that “more medications” is not synonymous with “better outcomes,” and that careful reduction of unnecessary drugs can improve quality of life, cognition, and safety.

Conclusion

Deprescribing programs do not uniformly deliver 30% cognitive improvements, and such specific claims should be approached skeptically without rigorous evidence to support them. However, deprescribing is a scientifically sound, evidence-based approach that can meaningfully improve medication safety, reduce side effects, and in some cases enhance cognitive clarity by eliminating drugs that impair thinking. The research shows these programs are generally safe, that they sometimes improve functional abilities, and that high-risk medications like anticholinergics, benzodiazepines, and antipsychotics are appropriate targets—though with important caveats around monitoring and gradual tapering.

If deprescribing is being considered for someone in your care, the first step is a comprehensive medication review by a knowledgeable clinician such as a geriatrician or clinical pharmacist. The second is a thoughtful conversation with the patient and family about which medications might be candidates, what benefits are expected, what risks exist during the transition, and what monitoring will occur. Deprescribing is not about removing all medications, but about aligning medications with actual medical needs and tolerances—a goal that, when achieved thoughtfully, can enhance both the quality and clarity of life in dementia care.